Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson's disease and depression: effect on quality of life.
Identifieur interne : 002C80 ( PubMed/Corpus ); précédent : 002C79; suivant : 002C81Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson's disease and depression: effect on quality of life.
Auteurs : Angelo Antonini ; Silvana Tesei ; Anna Zecchinelli ; Paolo Barone ; Danilo De Gaspari ; Margherita Canesi ; Giorgio Sacilotto ; Nicoletta Meucci ; Claudio Mariani ; Gianni PezzoliSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2006.
English descriptors
- KwdEn :
- Amitriptyline (therapeutic use), Antidepressive Agents (therapeutic use), Depression (etiology), Depression (prevention & control), Female, Humans, Male, Middle Aged, Parkinson Disease (psychology), Quality of Life, Serotonin Uptake Inhibitors (therapeutic use), Sertraline (therapeutic use), Single-Blind Method.
- MESH :
- chemical , therapeutic use : Amitriptyline, Antidepressive Agents, Serotonin Uptake Inhibitors, Sertraline.
- etiology : Depression.
- prevention & control : Depression.
- psychology : Parkinson Disease.
- Female, Humans, Male, Middle Aged, Quality of Life, Single-Blind Method.
Abstract
We assessed the effect of 3-month treatment of sertraline (50 mg) or low-dose amitriptyline (25 mg) on depression and quality of life in 31 patients with Parkinson's disease in a prospective single-blind randomized study. Both drugs significantly reduced the Hamilton Depression Rating Scale (HDRS-17) score. Completion rate was 75% for sertraline (12 of 16) and 73% for amitriptyline (11 of 15). Responder rate (HDRS-17 score reduction >/= 50%) was 83.3% for sertraline and 72.7% for amitriptyline. Sertraline but not amitriptyline treatment determined a significant benefit on quality of life (PDQ-39 scale). We found no change in Unified Parkinson's Disease Rating Scale scores. However, the improvement in specific PDQ-39 subscores (mobility, activities of daily living, and stigma) suggests that depression affects patient self-perception of motor function and further emphasizes the need for its treatment.
DOI: 10.1002/mds.20895
PubMed: 16637039
Links to Exploration step
pubmed:16637039Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson's disease and depression: effect on quality of life.</title><author><name sortKey="Antonini, Angelo" sort="Antonini, Angelo" uniqKey="Antonini A" first="Angelo" last="Antonini">Angelo Antonini</name><affiliation><nlm:affiliation>Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Tesei, Silvana" sort="Tesei, Silvana" uniqKey="Tesei S" first="Silvana" last="Tesei">Silvana Tesei</name></author><author><name sortKey="Zecchinelli, Anna" sort="Zecchinelli, Anna" uniqKey="Zecchinelli A" first="Anna" last="Zecchinelli">Anna Zecchinelli</name></author><author><name sortKey="Barone, Paolo" sort="Barone, Paolo" uniqKey="Barone P" first="Paolo" last="Barone">Paolo Barone</name></author><author><name sortKey="De Gaspari, Danilo" sort="De Gaspari, Danilo" uniqKey="De Gaspari D" first="Danilo" last="De Gaspari">Danilo De Gaspari</name></author><author><name sortKey="Canesi, Margherita" sort="Canesi, Margherita" uniqKey="Canesi M" first="Margherita" last="Canesi">Margherita Canesi</name></author><author><name sortKey="Sacilotto, Giorgio" sort="Sacilotto, Giorgio" uniqKey="Sacilotto G" first="Giorgio" last="Sacilotto">Giorgio Sacilotto</name></author><author><name sortKey="Meucci, Nicoletta" sort="Meucci, Nicoletta" uniqKey="Meucci N" first="Nicoletta" last="Meucci">Nicoletta Meucci</name></author><author><name sortKey="Mariani, Claudio" sort="Mariani, Claudio" uniqKey="Mariani C" first="Claudio" last="Mariani">Claudio Mariani</name></author><author><name sortKey="Pezzoli, Gianni" sort="Pezzoli, Gianni" uniqKey="Pezzoli G" first="Gianni" last="Pezzoli">Gianni Pezzoli</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2006">2006</date><idno type="doi">10.1002/mds.20895</idno><idno type="RBID">pubmed:16637039</idno><idno type="pmid">16637039</idno><idno type="wicri:Area/PubMed/Corpus">002C80</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson's disease and depression: effect on quality of life.</title><author><name sortKey="Antonini, Angelo" sort="Antonini, Angelo" uniqKey="Antonini A" first="Angelo" last="Antonini">Angelo Antonini</name><affiliation><nlm:affiliation>Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Tesei, Silvana" sort="Tesei, Silvana" uniqKey="Tesei S" first="Silvana" last="Tesei">Silvana Tesei</name></author><author><name sortKey="Zecchinelli, Anna" sort="Zecchinelli, Anna" uniqKey="Zecchinelli A" first="Anna" last="Zecchinelli">Anna Zecchinelli</name></author><author><name sortKey="Barone, Paolo" sort="Barone, Paolo" uniqKey="Barone P" first="Paolo" last="Barone">Paolo Barone</name></author><author><name sortKey="De Gaspari, Danilo" sort="De Gaspari, Danilo" uniqKey="De Gaspari D" first="Danilo" last="De Gaspari">Danilo De Gaspari</name></author><author><name sortKey="Canesi, Margherita" sort="Canesi, Margherita" uniqKey="Canesi M" first="Margherita" last="Canesi">Margherita Canesi</name></author><author><name sortKey="Sacilotto, Giorgio" sort="Sacilotto, Giorgio" uniqKey="Sacilotto G" first="Giorgio" last="Sacilotto">Giorgio Sacilotto</name></author><author><name sortKey="Meucci, Nicoletta" sort="Meucci, Nicoletta" uniqKey="Meucci N" first="Nicoletta" last="Meucci">Nicoletta Meucci</name></author><author><name sortKey="Mariani, Claudio" sort="Mariani, Claudio" uniqKey="Mariani C" first="Claudio" last="Mariani">Claudio Mariani</name></author><author><name sortKey="Pezzoli, Gianni" sort="Pezzoli, Gianni" uniqKey="Pezzoli G" first="Gianni" last="Pezzoli">Gianni Pezzoli</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2006" type="published">2006</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Amitriptyline (therapeutic use)</term><term>Antidepressive Agents (therapeutic use)</term><term>Depression (etiology)</term><term>Depression (prevention & control)</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Parkinson Disease (psychology)</term><term>Quality of Life</term><term>Serotonin Uptake Inhibitors (therapeutic use)</term><term>Sertraline (therapeutic use)</term><term>Single-Blind Method</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Amitriptyline</term><term>Antidepressive Agents</term><term>Serotonin Uptake Inhibitors</term><term>Sertraline</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Depression</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Depression</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Quality of Life</term><term>Single-Blind Method</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We assessed the effect of 3-month treatment of sertraline (50 mg) or low-dose amitriptyline (25 mg) on depression and quality of life in 31 patients with Parkinson's disease in a prospective single-blind randomized study. Both drugs significantly reduced the Hamilton Depression Rating Scale (HDRS-17) score. Completion rate was 75% for sertraline (12 of 16) and 73% for amitriptyline (11 of 15). Responder rate (HDRS-17 score reduction >/= 50%) was 83.3% for sertraline and 72.7% for amitriptyline. Sertraline but not amitriptyline treatment determined a significant benefit on quality of life (PDQ-39 scale). We found no change in Unified Parkinson's Disease Rating Scale scores. However, the improvement in specific PDQ-39 subscores (mobility, activities of daily living, and stigma) suggests that depression affects patient self-perception of motor function and further emphasizes the need for its treatment.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">16637039</PMID><DateCreated><Year>2006</Year><Month>08</Month><Day>30</Day></DateCreated><DateCompleted><Year>2007</Year><Month>01</Month><Day>04</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>21</Volume><Issue>8</Issue><PubDate><Year>2006</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson's disease and depression: effect on quality of life.</ArticleTitle><Pagination><MedlinePgn>1119-22</MedlinePgn></Pagination><Abstract><AbstractText>We assessed the effect of 3-month treatment of sertraline (50 mg) or low-dose amitriptyline (25 mg) on depression and quality of life in 31 patients with Parkinson's disease in a prospective single-blind randomized study. Both drugs significantly reduced the Hamilton Depression Rating Scale (HDRS-17) score. Completion rate was 75% for sertraline (12 of 16) and 73% for amitriptyline (11 of 15). Responder rate (HDRS-17 score reduction >/= 50%) was 83.3% for sertraline and 72.7% for amitriptyline. Sertraline but not amitriptyline treatment determined a significant benefit on quality of life (PDQ-39 scale). We found no change in Unified Parkinson's Disease Rating Scale scores. However, the improvement in specific PDQ-39 subscores (mobility, activities of daily living, and stigma) suggests that depression affects patient self-perception of motor function and further emphasizes the need for its treatment.</AbstractText><CopyrightInformation>(c) 2006 Movement Disorder Society</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Antonini</LastName><ForeName>Angelo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tesei</LastName><ForeName>Silvana</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Zecchinelli</LastName><ForeName>Anna</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Barone</LastName><ForeName>Paolo</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>De Gaspari</LastName><ForeName>Danilo</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Canesi</LastName><ForeName>Margherita</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Sacilotto</LastName><ForeName>Giorgio</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Meucci</LastName><ForeName>Nicoletta</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Mariani</LastName><ForeName>Claudio</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Pezzoli</LastName><ForeName>Gianni</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017367">Serotonin Uptake Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>1806D8D52K</RegistryNumber><NameOfSubstance UI="D000639">Amitriptyline</NameOfSubstance></Chemical><Chemical><RegistryNumber>QUC7NX6WMB</RegistryNumber><NameOfSubstance UI="D020280">Sertraline</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000639">Amitriptyline</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000928">Antidepressive Agents</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003863">Depression</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000517">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000523">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D011788">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D017367">Serotonin Uptake Inhibitors</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D020280">Sertraline</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016037">Single-Blind Method</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>4</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>1</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>4</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1002/mds.20895</ArticleId><ArticleId IdType="pubmed">16637039</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002C80 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 002C80 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:16637039
|texte= Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson's disease and depression: effect on quality of life.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:16637039" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |